Business Wire

NY-KYNDRYL

20.9.2022 06:02:37 CEST | Business Wire | Press release

Share
Kyndryl Introduces New Platform, Kyndryl Bridge, to Orchestrate IT Estates and Drive Business Growth

Kyndryl (NYSE: KD), the world's largest IT infrastructure services provider, today announced a new open integration platform giving business leaders real-time insights into their complex IT estates, and unprecedented control over customizing their mission-critical operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005855/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kyndryl Introduces New Platform, Kyndryl Bridge, to Orchestrate IT Estates and Drive Business Growth (Graphic: Business Wire)

Kyndryl Bridge leverages Kyndryl’s core technology strengths. It marshals decades of expertise, operational data patterns and IP to generate actionable insights that redefine how enterprises improve and accelerate their AI-powered analytics and business objectives. In doing so, it creates an uninterrupted path between digital business and the tech that drives it. Kyndryl Bridge is designed to meet customers where they are today, enabling interoperability that maximizes the value of tools they already know and trust.

“Dealing with complexity is what Kyndryl does best, and what customers need most. Kyndryl Bridge will be a way for our customers, and Kyndryl, to run their mission-critical infrastructure and digital transformation journeys better,” said Martin Schroeter, Kyndryl’s Chairman and Chief Executive Officer. “Kyndryl is committed to transforming how IT services are delivered, and Kyndryl Bridge is core to our long-term strategic mission to grow our ecosystem of alliance partners, use tools and IP to create a robust advanced delivery system, and ultimately dedicate more expertise and focus to best serve customers at scale.”

Across the global economy, digital modernization efforts sit at the top of today’s business agendas, with 60 percent of CIOs citing it as their most critical growth driver in 2022. However, business and technology complexity — along with a shortage of critical IT skills — has slowed progress for most enterprises. Kyndryl is accelerating its customers’ digital business journeys by innovating to deliver solutions through platform-enabled services.

“Enterprise IT leaders today are responsible for the management of increasingly-complex IT estates that demand greater oversight, interoperability, and AI-powered analytics to avert challenges and downtime,” says David Tapper, program VP, Outsourcing and Managed Cloud Service at IDC. “The ability of Kyndryl Bridge to connect the many tools, workflows, and processes in which enterprises have spent years investing, while delivering real-time, actionable insights and recommendations, is a powerful proposition for enterprises throughout the global economy.”

Kyndryl Bridge integrates and connects the complex management and process tools that enterprises throughout the global economy rely upon. Its capabilities have, on average, reduced the number of incidents per server per month for enterprises by 74 percent.

“By enabling leaders to focus less on managing IT systems, they can build and support their digital business strategies while freeing up IT resources for higher-value work,” said Antoine Shagoury, Kyndryl’s Chief Technology Officer. “It provides greater access and control over critical tools, and Kyndryl experts in cloud, data and AI, security and resiliency, mainframe modernization, and other important aspects of the IT estate.”

Designed with configurability in mind, Kyndryl Bridge is evolving to deploy ready-made, industrial scale solutions from Kyndryl and its broad and growing partner ecosystem. Its intelligent management tools, powered by automation and AI, will provide technology leaders with real-time insights to prevent downtime and better forecast future needs and costs.

“As customers accelerate their digital transformation, Kyndryl’s new digital integration platform can help provide rich data insights, solutions automation, and services delivery expertise,” said Nick Holden, Vice President, Cisco Global Strategic Partners and Co-sell. “Kyndryl Bridge is a big step forward to enable Kyndryl and Cisco to deliver business outcomes that our joint customers are demanding.”

For customers, the platform maximizes the benefits of native multi-cloud capabilities and delivers an ‘as-a-service’ (aaS) operating environment. It is designed to be a strategic digital hub, that will continue to expand and grow over time, connecting Kyndryl’s advanced technology and tooling with a deep bench of industry expertise and forward-thinking innovators across virtually every sector of the global economy.

About Kyndryl
Kyndryl (NYSE: KD) is the world’s largest IT infrastructure services provider serving thousands of enterprise customers in more than 60 countries. The Company designs, builds, manages, and modernizes the complex, mission-critical information systems that the world depends on every day. For more information, visit www.kyndryl.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005855/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye